Crescita Therapeutics (TSX:CTX) ROCE % : -12.57% (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Crescita Therapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Crescita Therapeutics's annualized ROCE % for the quarter that ended in Mar. 2024 was -12.57%.

Crescita Therapeutics ROCE % Historical Data

The historical data trend for Crescita Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Crescita Therapeutics ROCE % Chart

Crescita Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

17.38

3.45

-3.48

2.52

-6.85

Crescita Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-1.51	-3.05	-24.09	1.34	-12.57

Crescita Therapeutics ROCE % Calculation

Crescita Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-1.445	/	( ( (28.484 - 6.057)	+	(24.598 - 4.864) )	/ 2 )
	=	-1.445	/	( (22.427	+	19.734)	/ 2 )
	=	-1.445	/	21.0805
	=	-6.85 %

Crescita Therapeutics's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-2.432	/	( ( (24.598 - 4.864)	+	(24.069 - 5.121) )	/ 2 )
	=	-2.432	/	( ( 19.734	+	18.948 )	/ 2 )
	=	-2.432	/	19.341
	=	-12.57 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Crescita Therapeutics (TSX:CTX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Crescita Therapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of Crescita Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Crescita Therapeutics (TSX:CTX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Crescita Therapeutics Inc (TSX:CTX) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

CRRTF:USA

Address

2805, Place Louis-R-Renaud, Laval, QC, CAN, H7V 0A3

Website

https://www.crescitatherapeutics.com

Crescita Therapeutics Inc is a Canadian commercial dermatology company with in-house research & development and manufacturing capabilities. The company offers a portfolio of non-prescription skincare products and early to commercial-stage prescription drug products and owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active ingredients into or through the skin. The company has three reportable segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The firm generates its revenue in the form of product sales and out-licensing revenue.

Executives

Knight Therapeutics Inc.

10% Security Holder

Crescita Therapeutics (TSX:CTX) Headlines

No Headlines